DBV Technologies to Attend Upcoming Investor Conferences
| Montrouge, France, May 1, 2018 |
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following investor conferences in May 2018:
Susanna Mesa, Chief Business Officer, will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA, on Tuesday, May 8, 2018, at 10:40 am ET.
David Schilansky, Deputy Chief Executive Officer, and Susanna Mesa, Chief Business Officer, will present at the Bank of America Merrill Lynch Health Care Conference 2018 in Las Vegas, NV, on Wednesday, May 16, 2018, at 9:20 am PT.
David Schilansky, Deputy Chief Executive Officer, will host investor meetings at the Gilbert Dupont 16th Annual Healthcare Conference on Tuesday, May 29, 2018, in Paris, France.
Susanna Mesa, Chief Business Officer, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Thursday, May 31, 2018, at 9:00 am PT.
Live webcasts of the Company presentations at the Deutsche Bank 43rd Annual Health Care Conference and the Bank of America Merrill Lynch Health Care Conference 2018 will be available on the Investor Relations section of the Company's website: https://www.dbv-technologies.com/investor-relations/. Replays of the presentations will also be available on DBV's website within three hours after the events.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company's ordinary shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com
DBV Media Contact
Raul Damas
Partner, Brunswick Group
+1-212-333-3810
DBV@brunswickgroup.com
Attachment